A
34.19
-1.16 (-3.28%)
| 前收盘价格 | 35.35 |
| 收盘价格 | 35.39 |
| 成交量 | 386,480 |
| 平均成交量 (3个月) | 800,312 |
| 市值 | 1,949,862,400 |
| 市盈率 (P/E TTM) | 2.93 |
| 价格/销量 (P/S) | 102.02 |
| 股市价格/股市净资产 (P/B) | 2.06 |
| 52周波幅 | |
| 利润日期 | 13 Feb 2025 - 17 Feb 2025 |
| 营业毛利率 | 2,051.38% |
| 营业利益率 (TTM) | -1,146.93% |
| 稀释每股收益 (EPS TTM) | 11.66 |
| 季度收入增长率 (YOY) | 21.20% |
| 总债务/股东权益 (D/E MRQ) | 3.74% |
| 流动比率 (MRQ) | 8.99 |
| 营业现金流 (OCF TTM) | -329.16 M |
| 杠杆自由现金流 (LFCF TTM) | -157.06 M |
| 资产报酬率 (ROA TTM) | -18.17% |
| 股东权益报酬率 (ROE TTM) | 53.65% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Agios Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.2
| 分析师共识 | 3.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.20 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.51% |
| 机构持股比例 | 106.85% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Farallon Capital Management Llc | 30 Sep 2024 | 5,660,866 |
| Armistice Capital, Llc | 30 Sep 2024 | 2,207,070 |
| Erste Asset Management Gmbh | 30 Sep 2024 | 2,184,900 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 75.00 (Scotiabank, 119.36%) | 购买 |
| 中 | 56.50 (65.25%) | |
| 低 | 51.00 (Raymond James, 49.17%) | 购买 |
| 平均值 | 59.75 (74.76%) | |
| 总计 | 3 购买, 1 保留 | |
| 平均价格@调整类型 | 45.52 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| RBC Capital | 10 Dec 2024 | 57.00 (66.72%) | 购买 | 46.02 |
| 01 Nov 2024 | 55.00 (60.87%) | 购买 | 44.87 | |
| Scotiabank | 09 Dec 2024 | 75.00 (119.36%) | 购买 | 48.64 |
| 01 Nov 2024 | 53.00 (55.02%) | 购买 | 44.87 | |
| Raymond James | 10 Oct 2024 | 51.00 (49.17%) | 购买 | 41.82 |
| Leerink Partners | 27 Sep 2024 | 56.00 (63.79%) | 保留 | 45.61 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合